Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scilex Holding CoSCLX -3.04%57 3-Year Share Buyback Ratio is -20.30 as of Jun. 2026. GuruFocus rates SCLX with a GF Score™ of 57/100 and a GF Value™ of $6.35 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 646 Drug Manufacturers companies, Scilex Holding Co ranks worse than 84.37% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Scilex Holding Co's current 3-Year Share Buyback Ratio was -20.30%.
The historical rank and industry rank for Scilex Holding Co's 3-Year Share Buyback Ratio or its related term are showing as below:
SCLX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3 Med: -4.6 Max: 10.8
Current: -20.3
During the past 7 years, Scilex Holding Co's highest 3-Year Share Buyback Ratio was 10.80%. The lowest was -20.30%. And the median was -4.60%.
SCLX's 3-Year Share Buyback Ratio is ranked worse than 84.37% of 646
companies
in the Drug Manufacturers industry
Industry Median: -2.1
vs SCLX: -20.30
Scilex Holding Co (NAS:SCLX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Scilex Holding Co 3-Year Share Buyback Ratio Related Terms
SCLX vs MIRA, NSRX, MDCX: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's 3-Year Share Buyback Ratio falls into.
Scilex Holding Co 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -20.30 mean?
Scilex Holding Co (SCLX) has a 3-Year Share Buyback Ratio of -20.30 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Scilex Holding Co and its competitors. According to the industry distribution chart, Scilex Holding Co ranks #545 out of 646 companies in the Drug Manufacturers industry, placing it in the top 84.4%.
Is Scilex Holding Co's 3-Year Share Buyback Ratio too high?
Scilex Holding Co's current 3-Year Share Buyback Ratio is -20.30. Based on the distribution chart, Scilex Holding Co ranks #545 out of 646 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scilex Holding Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's 3-Year Share Buyback Ratio compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #545 out of 646 companies for 3-Year Share Buyback Ratio. This places Scilex Holding Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Scilex Holding Co and its competitors. Scilex Holding Co's current 3-Year Share Buyback Ratio is -20.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.35, compared to a current price of $5.44 — trading 14.3% below its estimated fair value. The current 3-Year Share Buyback Ratio is -20.30. Scilex Holding Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current 3-Year Share Buyback Ratio is -20.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (SCLX) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be undervalued.
The current stock price of $5.44 is trading 14.3% below its estimated GF Value™ of $6.35.
GuruFocus considers Scilex Holding Co to be Modestly Undervalued.
Key valuation signals for SCLX:
3-Year Share Buyback Ratio: -20.30
GF Value™: $6.35 vs. price of $5.44 (14.3% below fair value)
No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
57GF Score
Get the complete analysis for SCLX
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCLX has been successfully added to your 
